Weight management
built on metabolic health.
Obesity is a metabolic disease. Treatment should start with understanding why weight is accumulating, not just how much.
InBody body composition
Skeletal muscle, visceral fat, and body fat percentage tracked at every visit — not just scale weight.
Full endocrine evaluation
Insulin resistance, thyroid function, PCOS, and perimenopausal hormone changes evaluated as part of the clinical picture.
GLP-1 medications when appropriate
Wegovy, Zepbound, and other anti-obesity medications as one part of a broader metabolic plan.
Long-term maintenance planning
Muscle preservation, regain prevention, and durable metabolic improvement — not a number reached and abandoned.
Weight gain is not always a simple calorie problem.
Insulin signaling
Appetite regulation
Sleep architecture
Stress physiology
Metabolic adaptation
Hormonal shifts
Medications
PCOS & thyroid disease
Many patients arrive at Well Endocrinology having already tried multiple diets, exercise programs, or medications. Others notice significant changes during perimenopause, after pregnancy, or alongside conditions like PCOS or insulin resistance, often without any change in their habits.
Weight regulation is influenced by more than calories in and calories out. Insulin signaling, appetite regulation, sleep architecture, stress physiology, and metabolic adaptation after repeated dieting all affect how the body stores and responds to fat.
Many patients with significant metabolic dysfunction have completely normal fasting glucose and normal thyroid panels. Standard lab work often misses it entirely.
A proper obesity medicine evaluation accounts for those factors. That is the starting point here.
Body composition matters more than scale weight.
Two patients can lose the same number of pounds while having very different metabolic outcomes. Rapid weight loss without attention to muscle preservation can worsen long-term insulin sensitivity and increase the likelihood of regain. At Well Endocrinology, InBody body composition analysis is used at every visit.
Skeletal muscle mass
Preserving lean mass during weight loss is the single most important factor in long-term metabolic outcomes and regain prevention.
Body fat percentage
Scale weight and BMI do not distinguish fat from muscle. Body fat percentage gives a clinically meaningful picture that neither metric provides.
Basal metabolic rate
Repeated dieting and rapid weight loss suppress BMR over time. Tracking it directly informs dosing decisions, nutrition targets, and why the same approach that worked before may no longer be working.
The target is not a lower number on the scale. The target is a better metabolic picture.
Midlife weight gain requires a different clinical approach.
Declining estrogen
Shifts fat distribution centrally, independent of caloric intake or activity level.
Sleep disruption
Nearly universal during perimenopause. Worsens cortisol dynamics and appetite regulation.
Lean mass decline
Accelerates during hormonal transition, reducing BMR and increasing fat gain even without dietary changes.
Worsening insulin sensitivity
Estrogen has a protective effect on insulin signaling. As levels fall, insulin resistance often worsens.
Women in perimenopause frequently notice significant changes in body composition, even when their habits have not changed. This is not a discipline problem. It is a metabolic shift.
The metabolic environment at 38 is not the same environment at 48. Treatment approaches that worked earlier in adulthood may not be appropriate now — and applying them without accounting for the hormonal context is one of the most common reasons midlife weight management fails.
At Well Endocrinology, obesity medicine during midlife is managed alongside hormonal evaluation. For patients where hormone therapy is also appropriate, both are addressed together rather than in separate silos.
Perimenopause & menopause care →Individualized. Evidence-based. Built for the long term.
Treatment plans are individualized. There is no standard protocol applied across patients. Depending on the clinical picture, the approach is built around what is actually driving weight gain, not a default prescription.
Metabolic evaluation
Comprehensive assessment of insulin resistance, hormonal status, thyroid function, sleep, medications, and body composition before any treatment decisions are made.
Nutrition & resistance training
Nutrition strategy focused on protein adequacy and metabolic health. Resistance training guidance to preserve lean mass during active weight loss.
Sleep & insulin resistance
Sleep optimization and insulin resistance management as primary treatment targets, not afterthoughts. Both have direct effects on weight regulation.
GLP-1 & anti-obesity medications
Semaglutide, tirzepatide, and other anti-obesity medications when clinically appropriate, prescribed as part of a broader treatment strategy.
Body composition monitoring
InBody analysis at every visit tracks skeletal muscle mass, body fat percentage, and visceral fat. Adjustments are based on body composition, not scale weight alone.
Long-term maintenance planning
Regain prevention, muscle preservation, and sustainable nutrition are built into treatment from the beginning, not added later after progress stalls.
On GLP-1 medications: Medication is one tool, not a substitute for a clinical plan. For patients where GLP-1s are appropriate, the goal is to use them as part of a broader strategy that preserves muscle, improves metabolic markers, and supports long-term maintenance.
Short-term weight loss is common. Long-term maintenance is harder.
Regain is not a failure of willpower. It is a predictable physiologic response to inadequately managed weight loss.
Most approaches do not account for what happens after the initial loss — the metabolic adaptations, the muscle that was lost, the appetite signals that shifted. Treatment at Well Endocrinology builds muscle preservation, regain prevention, and sustainable nutrition into the plan from the start. The goal is durable metabolic improvement, not a number reached and then lost.
Insulin resistance, perimenopausal hormonal changes, sleep disruption, medications, stress physiology, and metabolic adaptation after repeated dieting can all affect weight regulation. Many patients with significant metabolic dysfunction still have normal fasting glucose and normal thyroid panels.
Yes, when clinically appropriate. Dr. Sadiq has prescribed GLP-1 medications since 2015 through her work in endocrinology and obesity medicine. Treatment includes body composition monitoring, metabolic evaluation, nutrition strategy, and long-term maintenance planning.
Most clinics focus on prescriptions and scale weight alone. At Well Endocrinology, obesity medicine is practiced within a full endocrinology context, with attention to insulin resistance, PCOS, menopause-related metabolic changes, thyroid disease, and body composition.
From the Well Endocrinology blog
GLP-1 Costs in 2025: Insurance Coverage, Pricing, and What Patients Should Know
Metabolic Syndrome: The Earlier Warning Sign Most Patients Are Missing
Your Menopause Cheat Sheet: What to Ask for When You Can’t Access Expert Care
The Direct-Care Approach to Obesity: Personalized Treatment for Long-Term Metabolic Health
Looking for a more thoughtful approach to weight management?
Work directly with a triple board-certified endocrinologist and obesity medicine specialist for comprehensive metabolic evaluation, body composition analysis, and evidence-based obesity care. No referral required.
Schedule consultation